Understanding Insulin and Medications for Blood Sugar Management

by

Managing blood sugar levels is a critical component of diabetes care that affects millions of people worldwide. Whether you have type 1 diabetes, type 2 diabetes, or are at risk of developing the condition, understanding how insulin and various medications work can empower you to make informed decisions about your treatment plan. This comprehensive guide explores the science behind insulin, the different types available, and the wide range of medications used to control blood sugar levels effectively.

What Is Insulin and Why Is It Important?

Insulin is a hormone that helps with energy regulation. After a meal, the pancreas releases insulin into the blood. Insulin’s main job is to get glucose out of the blood and into cells. This process is essential for maintaining healthy blood sugar levels and providing energy to every cell in your body.

When you eat, carbohydrates are broken down into glucose, which enters your bloodstream. In response, your pancreas releases insulin to help transport this glucose from the blood into your cells, where it can be used for immediate energy or stored for later use. The body’s cells need glucose for fuel. Insulin’s actions also help to keep glucose levels in the blood from getting too high.

When people do not make insulin, or their bodies do not respond to insulin the way they should, that’s called diabetes. In these cases, insulin medication can help to manage blood glucose levels. Understanding the role of insulin is fundamental to comprehending why diabetes management requires such careful attention to medication, diet, and lifestyle factors.

Types of Diabetes and Insulin Needs

Type 1 Diabetes

While insulin is the standard treatment for type 1 diabetes (T1D), it’s used less commonly for type 2 diabetes. With T1D, the pancreas makes little to no insulin, so people with T1D need to take extra insulin to help keep blood glucose within target range. People with type 1 diabetes require lifelong insulin therapy because their immune system has destroyed the insulin-producing beta cells in the pancreas.

Type 2 Diabetes

People with type 2 diabetes can still make insulin, but the body doesn’t use it effectively. That’s why some people with type 2 diabetes need to take prescription insulin. Many individuals with type 2 diabetes can initially manage their condition through lifestyle modifications and oral medications, but as the disease progresses, insulin therapy may become necessary to maintain optimal blood sugar control.

Understanding the Different Types of Insulin

The onset, peak, and duration of effect vary among insulin preparations. Commercially available insulins are categorized as rapid-acting, short-acting, intermediate-acting, and long-acting. Each type of insulin is designed to mimic different aspects of natural insulin secretion, allowing healthcare providers to create customized treatment plans that match individual needs.

Rapid-Acting Insulin

Rapid-acting insulins (lispro and aspart) start their action in 5 to 15 minutes and peak in 30 minutes. The duration of action is 3 to 5 hours. Examples include insulin lispro, (brand names: Admelog, Humalog), lispro-aabc (brand name: Lyumjev), insulin aspart (brand names: Fiasp, NovoLog), and insulin glulisine (brand name: Apidra).

They are generally used before meals and are always used along with short-acting or long-acting insulins to control sugar levels throughout the day. Rapid-acting insulin is injected before a meal to prevent your blood glucose from rising, and to correct high blood sugars. It can be used with a longer-acting insulin. The quick onset makes these insulins ideal for managing the blood sugar spike that occurs after eating.

Short-Acting Insulin (Regular Insulin)

Short-acting (regular insulin) starts the action in 30 to 40 minutes and peaks in 90 to 120 minutes. The duration of action is 6 to 8 hours. Examples include regular insulin (brand names: Humulin R, Novolin R).

Patients take these agents before meals, and food is necessary within 30 minutes after its administration to avoid hypoglycemia. Regular insulin has a delayed onset of action of 30-60 minutes, and should be injected approximately 30 minutes before the meal to blunt the postprandial rise in blood glucose. This timing requirement makes regular insulin slightly less convenient than rapid-acting analogs, but it remains an effective and affordable option for many patients.

Intermediate-Acting Insulin

Intermediate-acting insulins (NPH) start the action in 1 to 4 hours and peak in 4 to 8 hours. Dosing is usually twice a day and helps maintain blood sugar levels throughout the day. NPH insulin is an intermediate-acting insulin, with an onset of action of approximately 2 hours, peak effect 6-14 hours, and duration of action 10-16 hours (depending on the size of the dose).

This type of insulin takes about 2 to 4 hours to start working and peaks at about 4 to 12 hours after injection. The effective duration is 12 to18 hours. Examples include NPH insulin (brand names: Humulin N, Novolin N). NPH insulin can provide both basal coverage throughout the day and some mealtime coverage, making it a versatile option for certain treatment regimens.

Long-Acting Insulin

Long acting insulin analogs (Insulin Glargine, Insulin Detemir and Insulin Degludec) have an onset of insulin effect in 1 1/2 – 2 hours. The insulin effect plateaus over the next few hours and is followed by a relatively flat duration of action that lasts 12-24 hours for insulin detemir, 24 hours for insulin glargine and 36 hours for insulin degludec.

Basal insulin analogs have longer duration of action with flatter, more constant and consistent plasma concentrations and activity profiles than NPH insulin. This “peakless” profile more closely mimics the body’s natural basal insulin secretion, reducing the risk of hypoglycemia between meals and overnight. Long-acting insulins provide the foundation for many insulin regimens, maintaining steady blood sugar levels throughout the day and night.

Inhaled Insulin

In 2014, the FDA approved an inhalable insulin formulation. It passes through the lungs and into the bloodstream and provides a rapid onset of action within 12 minutes. It can be taken by patients with diabetes type 1 and type 2 before meals. Inhaled insulin is rapid-acting and starts working within 12-15 minutes of being inhaled. It leaves your body within 3 hours and peaks within 30 minutes of being inhaled. This type of insulin can’t be used in place of long-acting insulin but should be combined with it.

Inhaled insulin offers a needle-free alternative for mealtime insulin coverage, which can be particularly appealing for individuals who have difficulty with injections. However, it’s not suitable for everyone and requires specific considerations regarding lung function.

Pre-Mixed and Combination Insulins

Combination Insulin/Pre-Mixed/Fixed Combination combines different types of insulin into 1 injection. It starts working within 5 to 60 minutes. The peaks vary and the duration is anywhere from 10 to 24 hours. Examples include the brand names: Humalog Mix 75/25, Humalog Mix 50/50, NovoLog Mix 70/30, and Novolin 70/30.

NPH insulin or protamine added to rapid-acting insulin analogs can be mixed together with regular or rapid-acting insulin analogs in fixed combinations. These insulins thus provide bolus insulin coverage for the meal that follows the injections well as basal coverage from the intermediate-acting component of the insulin. While convenient, these fixed-ratio combinations offer less flexibility than separate basal and bolus insulin injections.

Insulin Delivery Methods

Insulin Injections

The most common method of insulin delivery is subcutaneous injection using insulin syringes, insulin pens, or smart insulin pens. The concentration of insulin identifies the number of units of insulin in 1 milliliter (mL). The most commonly used concentration in the United States is U-100. The higher concentrations are used to decrease the volume of injection needed to administer an insulin dosage and are used when larger amounts of insulin are required for glucose management.

Insulin Pumps

The insulin pump is a device that works like a natural pancreas. It replaces the need for long-acting insulin and continuously delivers small amounts of short-acting insulin to the body throughout the day. An insulin pump is a small, wearable device that gives a continuous (basal) dose of rapid-acting insulin. When prompted, it will deliver a bolus dose of insulin for meals or to correct high glucose levels.

A systematic review and meta-analysis concluded that CSII via pump therapy has modest advantages for lowering A1C (−0.30% [95% CI −0.58 to −0.02]) and for reducing severe hypoglycemia rates in adults. Insulin pumps offer greater flexibility and precision in insulin delivery, making them an attractive option for many people with diabetes, particularly those with type 1 diabetes.

Insulin Therapy Regimens

Insulin replacement plans typically consist of basal insulin, mealtime insulin, and correction insulin. Basal insulin includes NPH insulin, long-acting insulin analogs, and continuous delivery of rapid-acting insulin via an insulin pump. The goal is to mimic the body’s natural insulin secretion pattern as closely as possible.

Basal-Bolus Regimen

Basal insulin (long-acting or ultra-long-acting) helps to manage blood glucose between meals. While bolus (rapid- or short-acting) insulin helps to manage blood glucose at meals. With a basal-bolus regimen, you may have four or more injections per day. This method may be recommended for people with T1D and T2D.

This approach provides the most flexibility in terms of meal timing and carbohydrate intake, as mealtime insulin doses can be adjusted based on what and when you eat. People with diabetes can have two ratios at meals to help them stay within target range. One is an insulin to carbohydrate ratio, the other is a sliding scale (or correction factor). Because blood glucose varies before meals, a correction factor is a good solution. This means that the amount of insulin given varies with the blood glucose value.

Multiple Daily Injections

The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy with multiple daily injections or continuous subcutaneous insulin infusion (CSII) reduced A1C and was associated with improved long-term outcomes. The study was carried out with short-acting (regular) and intermediate-acting (NPH) human insulins. In this landmark trial, lower A1C with intensive management (7.3%) led to ∼50% reductions in microvascular complications compared with 9.1% mean A1C in the conventional treatment arm over 6 years of treatment.

Potential Side Effects of Insulin Therapy

Hypoglycemia is, by far, the most common adverse effect of insulin therapy. The other adverse effects of insulin therapy include weight gain and rarely electrolyte disturbances like hypokalemia, especially when used along with other drugs causing hypokalemia. Understanding these potential side effects is crucial for safe and effective insulin use.

Hypoglycemia, or low blood sugar, occurs when insulin levels are too high relative to blood glucose levels. Symptoms can include shakiness, sweating, confusion, rapid heartbeat, and in severe cases, loss of consciousness. Patients using insulin should be educated about recognizing and treating hypoglycemia promptly with fast-acting carbohydrates.

Non-Insulin Medications for Blood Sugar Management

While insulin is essential for people with type 1 diabetes and many with type 2 diabetes, numerous other medications can help manage blood sugar levels. These medications work through various mechanisms and are often used in combination to achieve optimal glycemic control.

Metformin: The First-Line Treatment

Metformin has remained first-line treatment for T2DM due to its efficacy, safety, duration of evidence, affordability, and limited side-effect profile. Metformin lowers blood glucose levels primarily by decreasing the amount of glucose produced by the liver. Metformin also helps lower blood glucose levels by making muscle tissue more sensitive to insulin so blood glucose can be used for energy.

It is usually taken two times a day. A side effect of metformin may be diarrhea, but this is improved when the drug is taken with food. Metformin is generally well-tolerated and does not cause hypoglycemia when used alone, making it an excellent starting point for type 2 diabetes management.

Importantly, metformin should not be started in those whose eGFR is <45 mL/min/1.73 m2. For those already treated with metformin, the dose of metformin should be reduced once eGFR is <45 mL/min/1.73 m2 and should be stopped once eGFR is <30 mL/min/1.73 m2. This consideration is important for patients with kidney disease.

SGLT2 Inhibitors: A Newer Class with Multiple Benefits

Glucose in the bloodstream passes through the kidneys where it can either be excreted in the urine or reabsorbed back into the blood. Sodium-glucose cotransporter 2 (SGLT2) works in the kidney to reabsorb glucose. A new class of medication, SGLT2 inhibitors, block this action, causing excess glucose to be eliminated in the urine. By increasing the amount of glucose excreted in the urine, people can see improved blood glucose, some weight loss, and small decreases in blood pressure.

SGLT2 inhibitors are also known to help improve outcomes in people with heart disease, kidney disease, and heart failure. For this reason, these medications are often used in people with type 2 diabetes who also have heart or kidney problems. Examples of SGLT2 inhibitors include empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and bexagliflozin (Brenzavvy).

Because they increase glucose levels in the urine, the most common side effects include genital yeast infections. Other potential side effects include urinary tract infections and increased urination. Despite these considerations, SGLT2 inhibitors have become an important part of diabetes management due to their cardiovascular and renal protective effects.

GLP-1 Receptor Agonists: Injectable Medications with Powerful Effects

GLP-1 receptor agonists are injectable medications that act when blood glucose increases after eating. They increase insulin levels, which helps lower blood glucose and lower glucagon levels (a hormone that raises blood glucose). They also slow digestion and reduce appetite.

Possible side effects include nausea, which usually goes away with time. They are associated with weight loss and a low risk of hypoglycemia. Of the currently available agents, tirzepatide and semaglutide have the highest efficacy in terms of glucose lowering as well as weight loss, followed by dulaglutide, liraglutide, and extended-release exenatide.

One dual GLP-1/GIP receptor agonist is currently on the market called tirzepatide (Mounjaro). How often you need to inject these medications varies from twice daily to once weekly, depending on the medication. The most common side effect with these medications is nausea and vomiting, which is more common when starting or increasing the dose.

Increasing evidence supports the role of both SGLT2i and GLP1RA in reducing major adverse cardiac events and progression of renal disease while increasing weight loss and reducing blood pressure. SGLT2i accomplish this primarily via hemodynamic effects, whereas GLP1RAs have stronger anti-atherogenic effects.

Sulfonylureas: Traditional Insulin Secretagogues

Sulfonylureas have been in use since the 1950s and they stimulate beta cells in the pancreas to release more insulin. There are three main sulfonylurea drugs used today, glimepiride (Amaryl), glipizide (Glucotrol and Glucotrol XL), and glyburide (Micronase, Glynase, and Diabeta). These drugs are generally taken one to two times a day before meals.

The most common side effects with sulfonylureas are low blood glucose and weight gain. The place of sulfonylureas is controversial as they may induce hypoglycemia, and as suggested by the UGDP study, tolbutamide use may also be associated with an increased risk of cardiovascular mortality. Due to these concerns, sulfonylureas are generally considered after other medication options have been explored.

DPP-4 Inhibitors: Oral Incretin-Based Therapy

DPP-4 inhibitors help improve A1C (a measure of average blood glucose levels over two to three months) without causing hypoglycemia (low blood glucose). They work by preventing the breakdown of naturally occurring hormones in the body, GLP-1 and GIP. These medications enhance the body’s own incretin system, which helps regulate blood sugar in response to meals.

The DPP4 enzyme deactivates GLP1; thus DPP4 inhibition extends the function of endogenous GLP1. Beyond the glucose-lowering effects, DPP4i have neutral to beneficial effects on weight, blood pressure, postprandial lipid status, inflammation, oxidative stress, and endothelial function. DPP-4 inhibitors are generally well-tolerated and offer a convenient oral option for patients who prefer not to use injectable medications.

Thiazolidinediones (TZDs): Insulin Sensitizers

Rosiglitazone (Avandia) and pioglitazone (Actos) are in a group of drugs called thiazolidinediones. These drugs help insulin work better in the muscle and fat and reduce glucose production in the liver. A benefit of TZDs is that they lower blood glucose without having a high risk for causing low blood glucose.

Both drugs in this class can increase the risk for heart failure in some individuals and can also cause fluid retention (edema) in the legs and feet. Due to these potential side effects, TZDs are used more selectively and require careful monitoring, particularly in patients with heart failure or at risk for it.

Other Diabetes Medications

In addition to the commonly used classes discussed above, there are other less commonly used medications that can work well for some people. Acarbose (Precose) and miglitol (Glyset) are alpha-glucosidase inhibitors. These drugs help the body lower blood glucose levels by blocking the breakdown of starches, such as bread, potatoes, and pasta in the intestine.

Alpha-glucosidase inhibitors slow carbohydrate absorption in the digestive tract, helping to prevent post-meal blood sugar spikes. While effective, they can cause gastrointestinal side effects such as gas and bloating, which limits their use in some patients.

Combination Therapy Approaches

Many people with type 2 diabetes require more than one medication to achieve their blood sugar goals. Combination therapy uses medications with different mechanisms of action to provide more comprehensive blood sugar control.

Metformin-Based Combinations

Combinations of metformin with a sulfonylurea, a thiazolidinedione (TZD), an SGLT2 inhibitor and a DPP-4 inhibitor have comparable A1C-lowering effects, while the combination of metformin with a GLP-1 receptor agonist reduced A1C more than combination with a DPP-4 inhibitor.

TZDs, insulin and sulfonylureas are associated with the most weight gain (1.5 to 5.0 kg) when added to metformin, whereas GLP-1 receptor agonists and SGLT2 inhibitors are associated with weight loss. Hypoglycemia risk is also lower with TZDs, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists compared to sulfonylureas and insulin.

Triple Therapy Regimens

Among these triple combinations, metformin + DPP‐4i + SGLT2i demonstrated the highest proportion of patients achieving HbA1c <7.0% and the greatest improvement in blood pressure, with HbA1c reductions second only to metformin + SGLT2i + insulin. Triple therapy may be necessary for patients who don’t achieve adequate control with dual therapy.

The combinations of metformin and different SGLT2 inhibitor drugs have an encouraging efficacy in the management of T2D, including better glycemic improvements, weight loss, blood pressure control, etc. In addition to these advantages, the combination of metformin-SGLT2 inhibitors also showed potential benefits in cardiovascular and renal protection, providing comprehensive protection for patients with T2D.

Combining Insulin with Other Medications

When initiating intensification of insulin therapy, metformin, SGLT2 inhibitors, and GLP-1 RAs (or a dual GIP and GLP-1 RA) should be maintained, unless adverse effects (including significant treatment burden) or contraindications are present. This approach maximizes the benefits of each medication class while minimizing side effects.

Use of sulfonylureas, meglitinides, and DPP-4 inhibitors should be limited or discontinued, as these medications do not have additional beneficial effects on cardiovascular, kidney, weight, or liver outcomes. The choice of combination therapy should be individualized based on patient characteristics, comorbidities, and treatment goals.

Personalizing Diabetes Treatment

A doctor will consider blood glucose levels, health history, and lifestyle when recommending the most suitable insulin type, which may change over time. Diabetes management is not one-size-fits-all, and treatment plans should be tailored to each individual’s unique circumstances.

Factors Influencing Treatment Decisions

Several factors influence the choice of diabetes medications, including:

  • Efficacy: How effectively the medication lowers blood sugar
  • Safety profile: Risk of hypoglycemia, weight gain, and other side effects
  • Cardiovascular and renal effects: Additional benefits beyond glucose lowering
  • Patient preferences: Oral versus injectable medications, dosing frequency
  • Cost and insurance coverage: Affordability and accessibility
  • Comorbidities: Presence of heart disease, kidney disease, obesity, or other conditions
  • Hypoglycemia risk: Particularly important for elderly patients or those with impaired awareness

Special Considerations for Different Patient Populations

Obesity is present in over 90% of people with type 2 diabetes, and in these individuals weight management is a key treatment goal, along with glucose lowering. In the setting of obesity, the choice of glucose-lowering medications should take into consideration their effects on weight. Insulins, sulfonylureas, and thiazolidinediones can promote weight gain and should be used judiciously and at the lowest possible dose. Glucose-lowering medications that promote weight loss should be prioritized.

Individuals with CKD, particularly advanced CKD and kidney failure, are at high risk for hypoglycemia. If treated with insulin and/or sulfonylureas, treatment needs to be closely monitored and adjusted as eGFR declines and individuals need to be educated about and closely monitored for hypoglycemia occurrence.

Current Guidelines and Recommendations

The 2020 updated ADA guidelines continue to recommend metformin as first-line therapy for all comers, with consideration of concurrent therapy with SGLTi in patients with HF or kidney disease and SGLT2i or GLP1RA in patients with predominantly atherosclerotic CVD. These guidelines reflect the growing evidence for the cardiovascular and renal benefits of newer diabetes medications.

The ADA recommends that patients who do not achieve their HbA1c goal after 3 months of metformin monotherapy should proceed to dual therapy with an additional antihyperglycemic medication, chosen based on patient-specific factors. SGLT2 inhibitors are one of six drug classes recommended for consideration in dual therapy by the ADA. These six drug classes include thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, basal insulin, and SGLT2 inhibitors.

We have entered a new era of pharmacologic therapy for T2DM, in which medications now prioritize treating the multiorgan vascular impacts of the disease. Use of SGLT2i and GLP1RA, on a background of metformin, have demonstrated strong evidence for treatment and prevention of atherosclerotic cardiovascular disease associated with T2DM. These new drug classes also show promise in treatment and prevention of renal disease and HF.

Monitoring and Adjusting Treatment

Successful diabetes management requires ongoing monitoring and adjustment of treatment plans. Regular blood sugar monitoring, whether through traditional fingerstick testing or continuous glucose monitoring (CGM), provides valuable information about how well your current regimen is working.

Continuous glucose monitoring improves outcomes with injected or infused insulin and is superior to blood glucose monitoring. CGM technology has revolutionized diabetes care by providing real-time glucose data and trend information, allowing for more precise insulin dosing and earlier detection of problematic patterns.

Hemoglobin A1C testing, typically performed every three to six months, provides a measure of average blood sugar control over the previous two to three months. This test helps healthcare providers assess the overall effectiveness of your treatment plan and make necessary adjustments.

The Importance of Lifestyle Factors

While medications play a crucial role in diabetes management, they work best when combined with healthy lifestyle habits. Diet, physical activity, stress management, and adequate sleep all significantly impact blood sugar control.

A balanced diet that emphasizes whole grains, lean proteins, healthy fats, and plenty of vegetables can help stabilize blood sugar levels and reduce medication requirements. Regular physical activity improves insulin sensitivity, helping your body use insulin more effectively. Even modest weight loss of 5-10% of body weight can significantly improve blood sugar control in people with type 2 diabetes.

Stress management is also important, as stress hormones can raise blood sugar levels. Techniques such as meditation, deep breathing exercises, yoga, or regular physical activity can help manage stress effectively. Quality sleep is equally important, as poor sleep can affect insulin sensitivity and blood sugar control.

Working with Your Healthcare Team

Managing diabetes effectively requires a collaborative approach involving you and your healthcare team. This team may include your primary care physician, endocrinologist, diabetes educator, dietitian, pharmacist, and other specialists as needed.

Regular communication with your healthcare providers is essential. Be sure to report any difficulties with your current regimen, including side effects, challenges with medication adherence, or concerns about costs. Your healthcare team can work with you to find solutions that fit your lifestyle and budget while still achieving your blood sugar goals.

Diabetes education is a crucial component of successful management. Understanding how different foods affect your blood sugar, how to properly administer insulin, how to recognize and treat hypoglycemia, and how to adjust your medications during illness are all important skills that diabetes educators can help you develop.

Looking Ahead: Future Developments in Diabetes Treatment

Longer duration, long-acting insulins are on the horizon, including a weekly long-acting insulin. The field of diabetes treatment continues to evolve rapidly, with new medications and technologies constantly being developed and refined.

Automated insulin delivery systems, sometimes called “artificial pancreas” systems, combine continuous glucose monitoring with insulin pumps and sophisticated algorithms to automatically adjust insulin delivery. These systems are becoming increasingly sophisticated and accessible, offering improved glucose control with reduced burden on patients.

Research into new medication classes continues, with scientists exploring novel mechanisms for lowering blood sugar and protecting against diabetes complications. Gene therapy, beta cell replacement, and immunotherapy approaches for type 1 diabetes are also areas of active investigation.

Key Takeaways for Effective Blood Sugar Management

Understanding insulin and diabetes medications is fundamental to effective blood sugar management. Here are the key points to remember:

  • Insulin is essential for people with type 1 diabetes and many with type 2 diabetes, with different types designed to mimic natural insulin secretion patterns
  • Multiple non-insulin medications are available, each working through different mechanisms to lower blood sugar
  • Metformin remains the first-line treatment for most people with type 2 diabetes due to its efficacy, safety, and affordability
  • Newer medications like SGLT2 inhibitors and GLP-1 receptor agonists offer additional cardiovascular and renal benefits beyond glucose lowering
  • Combination therapy is often necessary to achieve optimal blood sugar control
  • Treatment should be personalized based on individual patient characteristics, preferences, and comorbidities
  • Regular monitoring and adjustment of treatment plans are essential for long-term success
  • Lifestyle factors including diet, exercise, stress management, and sleep play crucial roles in blood sugar control
  • Working closely with your healthcare team ensures you receive the most appropriate and effective treatment

Conclusion

Managing blood sugar levels through insulin and medications is a complex but manageable aspect of diabetes care. With the wide array of treatment options now available, most people with diabetes can achieve good blood sugar control and reduce their risk of complications. The key is understanding how these medications work, working closely with your healthcare team to find the right combination for you, and maintaining healthy lifestyle habits that support your treatment plan.

As research continues and new treatments emerge, the outlook for people with diabetes continues to improve. By staying informed about your treatment options and actively participating in your care, you can take control of your diabetes and live a full, healthy life. Remember that diabetes management is a journey, not a destination, and it’s normal for your treatment plan to evolve over time as your needs change and new options become available.

For more information about diabetes management and treatment options, visit the American Diabetes Association, the Centers for Disease Control and Prevention Diabetes Resources, or consult with your healthcare provider about the best approach for your individual situation.